

ASX Announcement

18 June 2026

BlinkLab Granted Foundational U.S. Patent Covering Remote Neurobehavioural Testing Platform

Highlights

- **U.S. patent granted:** United States Patent and Trademark Office grants patent protecting BlinkLab's core remote neurobehavioral assessment technology, with exclusivity extending to 2041.
- **Strengthening of BlinkLab's intellectual property portfolio:** Provides long-term protection for core technology underpinning BlinkLab's digital biomarker platform and supports future clinical, regulatory and commercial activities in key healthcare markets.

BlinkLab Limited (ASX:BB1) ("BlinkLab" or the "Company"), a developer of AI-powered, smartphone-based neurobehavioural assessment technology, is pleased to announce that a key patent underpinning its digital neurobehavioral assessment platform has been granted by the United States Patent and Trademark Office (USPTO).

The patent, titled "System and Method for Remote Neurobehavioral Testing", was granted as U.S. Patent No. 12,653,444 B2. The patent is expected to remain in force until November 2041, subject to the payment of maintenance fees and any applicable patent term adjustments. The patent application was filed by **The Trustees of Princeton University** on 10 November 2021. The patented technology was invented by Princeton University neuroscientists and BlinkLab co-founders, **Dr Henk-Jan Boele** and **Prof. Samuel S.-H. Wang**.

BlinkLab holds an exclusive worldwide licence to the patented technology from Princeton University. The patent covers systems and methods for remote neurobehavioral assessment using audiovisual stimuli, including conditioned eyeblink responses and prepulse inhibition. These techniques form a fundamental component of BlinkLab's proprietary digital biomarker platform and have been incorporated into the Company's smartphone-based assessments for autism spectrum disorder and other neurodevelopmental conditions.

The grant provides intellectual property protection in the United States, the world's largest healthcare market, and further strengthens BlinkLab's growing portfolio of licensed and proprietary intellectual property.

BlinkLab Chief Executive Officer and Managing Director, Dr Henk-Jan Boele, commented:

"The grant of this U.S. patent of our invention is an important step for BlinkLab as we continue building a scalable platform for objective neurological assessment. It protects core technology that enables us to measure neurobehavioral responses remotely using everyday consumer devices such

as smartphones. That capability sits at the heart of our mission to make neurological testing more accessible, affordable and available to people regardless of where they live. As we advance our autism diagnostic programs and explore applications in other neurological and neurodevelopmental conditions, a strong intellectual property portfolio is an important part of creating long-term value. The U.S. is the world's largest healthcare market, and securing protection for this technology supports our future clinical, regulatory and commercial plans."

The patent grant further enhances the Company's ability to develop and commercialise objective digital biomarkers for neurological and neurodevelopmental disorders. BlinkLab continues to expand its intellectual property portfolio through a combination of licensed patents, internally developed technology and ongoing research collaborations.

This announcement has been authorised for release by the Managing Director of BlinkLab Limited.

For further information please contact:

Dr Henk-Jan Boele

Managing Director & CEO

henkjan@blinklab.org

M: +31 (0) 611 132 247

Brian Leedman

Non-Executive Chairman

brian@blinklab.org

M: +61 (0) 412 281 780

About BlinkLab Limited

BlinkLab Limited was founded by neuroscientists at Princeton University and is developing a smartphone-based diagnostic platform for autism. Its most advanced product, BlinkLab Dx 1, is an autism diagnostic aid for clinicians that leverages smartphones, artificial intelligence, and machine learning to capture objective, reflex-based measures, supporting earlier and more accurate autism identification. This enables timely intervention during critical periods of brain development. BlinkLab is led by an experienced management team and Board with deep expertise in digital healthcare, computer vision, and AI, supported by a Scientific Advisory Board of leading experts in autism and brain development.